In a Law360 article, capital markets partner Tom Danielski discussed the outlook for biotechnology initial public offerings (IPOs) in 2025.
Tom expects biotech IPOs to be slower as a result of market uncertainty and that companies are in a "wait-and-see mode" for the next few months. He anticipates that by the end of the second quarter or into the third quarter there may be a ramp-up in biotech IPOs.
Attorneys
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.